Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
Abstract Background The safety and efficacy of transarterial chemoembolization plus molecular targeted therapy (MTT) combined with immune checkpoint inhibitors (ICIs) in primary liver cancer have been demonstrated. However, the evidence for TACE plus MTT combined with ICIs in the treatment of recurr...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-12144-6 |
| _version_ | 1797233526477684736 |
|---|---|
| author | Changlong Hou Baizhu Xiong Lei Zhou Yipeng Fei Changgao Shi Xianhai Zhu Tao Xie Yulin Wu |
| author_facet | Changlong Hou Baizhu Xiong Lei Zhou Yipeng Fei Changgao Shi Xianhai Zhu Tao Xie Yulin Wu |
| author_sort | Changlong Hou |
| collection | DOAJ |
| description | Abstract Background The safety and efficacy of transarterial chemoembolization plus molecular targeted therapy (MTT) combined with immune checkpoint inhibitors (ICIs) in primary liver cancer have been demonstrated. However, the evidence for TACE plus MTT combined with ICIs in the treatment of recurrent hepatocellular carcinoma (RHCC) is limited. Given the excellent performance of this combination regimen in primary liver cancer, it is necessary to evaluate the efficacy of TACE plus MTT combined with ICIs in RHCC. Methods A total of 88 patients with RHCC treated with TACE plus MTT combined with camrelizumab (TACE-TC group, n = 46) or TACE plus MTT (TACE-T group, n = 42) were retrospectively collected and analyzed. In this study, we evaluated the effectiveness and safety of combination therapy for patients with RHCC by analyzing tumor response, progression-free survival (PFS), overall survival (OS), laboratory biochemical indices, and adverse events (AEs). Results TACE-TC was superior to TACE-T in PFS (14.0 vs. 8.9 months, p = 0.034) and OS (31.1 vs. 20.2 months, p = 0.009). Moreover, TACE-TC achieved more preferable benefits with respect to disease control rate (89.1% vs. 71.4%, p = 0.036) and objective response rate (47.8% vs. 26.2%, p = 0.036) compared with TACE-T in patients with RHCC. Compared with the TACE-T group, the AFP level in the TACE-TC group decreased more significantly after 3 months of treatment. Multivariate analysis showed that treatment option was a significant predictor of OS and PFS, while the portal vein tumor thrombus and interval of recurrence from initial treatment were another prognostic factor of PFS. There was no significant difference between the TACE-TC and TACE-T groups for Grade 3–4 adverse events. Conclusions A combination therapy of TACE, MTT, and camrelizumab significantly improved tumor response and prolonged survival duration, showing a better survival prognosis for RHCC patients. |
| first_indexed | 2024-04-24T16:17:34Z |
| format | Article |
| id | doaj.art-6925ef597ba54805992d185fde29e681 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-24T16:17:34Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-6925ef597ba54805992d185fde29e6812024-03-31T11:23:08ZengBMCBMC Cancer1471-24072024-03-0124111210.1186/s12885-024-12144-6Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinomaChanglong Hou0Baizhu Xiong1Lei Zhou2Yipeng Fei3Changgao Shi4Xianhai Zhu5Tao Xie6Yulin Wu7Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaAbstract Background The safety and efficacy of transarterial chemoembolization plus molecular targeted therapy (MTT) combined with immune checkpoint inhibitors (ICIs) in primary liver cancer have been demonstrated. However, the evidence for TACE plus MTT combined with ICIs in the treatment of recurrent hepatocellular carcinoma (RHCC) is limited. Given the excellent performance of this combination regimen in primary liver cancer, it is necessary to evaluate the efficacy of TACE plus MTT combined with ICIs in RHCC. Methods A total of 88 patients with RHCC treated with TACE plus MTT combined with camrelizumab (TACE-TC group, n = 46) or TACE plus MTT (TACE-T group, n = 42) were retrospectively collected and analyzed. In this study, we evaluated the effectiveness and safety of combination therapy for patients with RHCC by analyzing tumor response, progression-free survival (PFS), overall survival (OS), laboratory biochemical indices, and adverse events (AEs). Results TACE-TC was superior to TACE-T in PFS (14.0 vs. 8.9 months, p = 0.034) and OS (31.1 vs. 20.2 months, p = 0.009). Moreover, TACE-TC achieved more preferable benefits with respect to disease control rate (89.1% vs. 71.4%, p = 0.036) and objective response rate (47.8% vs. 26.2%, p = 0.036) compared with TACE-T in patients with RHCC. Compared with the TACE-T group, the AFP level in the TACE-TC group decreased more significantly after 3 months of treatment. Multivariate analysis showed that treatment option was a significant predictor of OS and PFS, while the portal vein tumor thrombus and interval of recurrence from initial treatment were another prognostic factor of PFS. There was no significant difference between the TACE-TC and TACE-T groups for Grade 3–4 adverse events. Conclusions A combination therapy of TACE, MTT, and camrelizumab significantly improved tumor response and prolonged survival duration, showing a better survival prognosis for RHCC patients.https://doi.org/10.1186/s12885-024-12144-6Hepatocellular carcinomaTransarterial chemoembolizationTargeted therapyImmune checkpoint inhibitorsInterventional treatment |
| spellingShingle | Changlong Hou Baizhu Xiong Lei Zhou Yipeng Fei Changgao Shi Xianhai Zhu Tao Xie Yulin Wu Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma BMC Cancer Hepatocellular carcinoma Transarterial chemoembolization Targeted therapy Immune checkpoint inhibitors Interventional treatment |
| title | Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma |
| title_full | Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma |
| title_fullStr | Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma |
| title_full_unstemmed | Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma |
| title_short | Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma |
| title_sort | transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma |
| topic | Hepatocellular carcinoma Transarterial chemoembolization Targeted therapy Immune checkpoint inhibitors Interventional treatment |
| url | https://doi.org/10.1186/s12885-024-12144-6 |
| work_keys_str_mv | AT changlonghou transarterialchemoembolizationwithmoleculartargetedtherapiespluscamrelizumabforrecurrenthepatocellularcarcinoma AT baizhuxiong transarterialchemoembolizationwithmoleculartargetedtherapiespluscamrelizumabforrecurrenthepatocellularcarcinoma AT leizhou transarterialchemoembolizationwithmoleculartargetedtherapiespluscamrelizumabforrecurrenthepatocellularcarcinoma AT yipengfei transarterialchemoembolizationwithmoleculartargetedtherapiespluscamrelizumabforrecurrenthepatocellularcarcinoma AT changgaoshi transarterialchemoembolizationwithmoleculartargetedtherapiespluscamrelizumabforrecurrenthepatocellularcarcinoma AT xianhaizhu transarterialchemoembolizationwithmoleculartargetedtherapiespluscamrelizumabforrecurrenthepatocellularcarcinoma AT taoxie transarterialchemoembolizationwithmoleculartargetedtherapiespluscamrelizumabforrecurrenthepatocellularcarcinoma AT yulinwu transarterialchemoembolizationwithmoleculartargetedtherapiespluscamrelizumabforrecurrenthepatocellularcarcinoma |